Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LAB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStandard Biotools shareholders approve new equity plan and 1.2M share ESPP expansion
Filed June 18, 2026 · Period ending June 17, 2026 · ~1 min read
Key Changes
-
medium
Stockholders approved 2026 Equity Incentive Plan, authorizing additional equity-based compensation for employees and directors, representing potential dilution to existing shareholders.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
ESPP share reserve increased by 1,200,000 shares (0.3% of outstanding), allowing employees to purchase stock at discount, approved with 95% support.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
Three Class I directors elected to three-year terms through 2029: Michael Egholm, Thomas Carey, and Eli Casdin, all receiving majority support.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
Executive compensation for 2025 approved on advisory basis with 85% shareholder support (209.8M for vs 36.3M against).
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
Annual meeting achieved 86% voter turnout (335.9M of 390.4M shares outstanding), with all five ballot proposals passing.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →
Summary
Standard Biotools held its 2026 annual meeting on June 17 with strong shareholder participation, and investors approved two equity compensation measures that will modestly dilute existing shares. The new 2026 Equity Incentive Plan passed with 228 million votes in favor, giving management fresh authorization to grant stock-based awards to employees and directors.
Separately, shareholders expanded the Employee Stock Purchase Plan by 1.2 million shares, representing about 0.3% dilution relative to the 390 million shares outstanding. For retail holders, these are routine governance matters reflecting management's need for competitive compensation tools in the biotech sector. The dilution is incremental rather than transformative.
All three director nominees won election to three-year terms, and the say-on-pay vote showed 85% approval of executive compensation, suggesting no major shareholder revolt over pay practices. Watch the company's next quarterly filing for details on how many shares are actually granted under the new plan and at what strike prices, which will determine the real dilutive impact on your position.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Stockholders approved 2026 Equity Incentive Plan and increased ESPP share reserve by 1,200,000 shares at Annual Meeting on June 17, 2026.
Added in current filing · verify on EDGAR →
The Company’s stockholders voted to approve the Company’s 2026 Equity Incentive Plan (the “2026 Plan”)
Stockholders approved a new equity incentive plan at the 2026 Annual Meeting held June 17, 2026. This plan will govern future equity compensation grants to employees, directors, and consultants. The approval allows the company to issue additional equity-based awards as part of its compensation strategy.
Added in current filing · verify on EDGAR →
an amendment to the Company’s Amended and Restated 2017 Employee Stock Purchase Plan (the “ESPP”), increasing the number of shares of common stock reserved for issuance thereunder by 1,200,000 shares
Stockholders approved adding 1,200,000 shares to the Employee Stock Purchase Plan reserve. This increases the pool of shares available for employee purchases under the ESPP, which typically allows employees to buy company stock at a discount. The increase represents potential dilution to existing shareholders but supports employee retention and alignment.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Standard Biotools held its 2026 annual meeting with 86% voter turnout; all proposals passed including director elections and equity plan approvals.
Added in current filing · verify on EDGAR →
The proposal to approve the 2026 Plan was approved by the following votes: Votes For | Votes Against | Abstentions | Broker Non-Votes | 228,342,854 | 17,821,911 | 3,616,833 | 86,119,046
Shareholders approved a new 2026 Equity Incentive Plan with 228.3 million votes for. This plan will authorize additional equity-based compensation for employees and directors, potentially diluting existing shareholders but providing retention and incentive tools for management.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
The following nominees were elected to serve as Class I directors, to hold office until the Company’s 2029 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified or their earlier resignation or removal: Nominee | Votes For | Votes Withheld | Broker Non-Votes | Michael Egholm, Ph.D. | 236,313,971 | 13,467,627 | 86,119,046 | Thomas Carey | 227,843,498 | 21,938,100 | 86,119,046 | Eli Casdin | 234,717,465 | 15,064,133 | 86,119,046
Three Class I directors were elected to three-year terms ending in 2029: Michael Egholm, Thomas Carey, and Eli Casdin. All three received majority support, with Egholm receiving the highest vote count at 236.3 million votes for.
Added in current filing · verify on EDGAR →
The proposal to approve the amendment to the ESPP to increase the shares of common stock reserved thereunder by 1,200,000 shares was approved by the following votes: Votes For | Votes Against | Abstentions | Broker Non-Votes | 237,474,844 | 12,276,507 | 30,247 | 86,119,046
Shareholders approved adding 1,200,000 shares to the Employee Stock Purchase Plan with 237.5 million votes for. This increases the pool available for employee stock purchases at discounted prices, representing modest additional dilution of approximately 0.3% of outstanding shares.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 18, 2026 · How we verify